secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anika Therapeutics, Inc. (ANIK)
CIK:        0000898437
Form:       8-K
Filed at:   2026-07-29T11:20:33+00:00
Accession:  0001171843-26-004977
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anika Q2 revenue $32.6M (+16% YoY); raises FY 2026 guidance, adj. EBITDA margin 13-17%
--------------------------------------------------------------------------------

- Q2 revenue $32.6M, up 16% YoY; Commercial Channel record $13.9M (+17%); OEM $18.7M (+14%).
- Gross margin 65%; net income $3.3M ($0.24 diluted EPS); adjusted EBITDA $7.1M (22% margin).
- Raising FY 2026 guidance: total revenue growth 5-10% (prev 1-9%); adj. EBITDA margin 13-17% (prev 5-10%).
- Revised 2027 Commercial revenue growth 5-15% (prev 10-20%); total company flat to 5% growth.
- International revenue record $12.6M (+22% YoY); Integrity units up 39% YTD; Hyalofast/Cingal progress.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/898437/000117184326004977/0001171843-26-004977-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/898437/000117184326004977/f8k_072926.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-004977

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer